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Purpose: Although the quality of life (QoL) of prostate cancer (PCa) patients is a major 
issue, there is no unified and useful methodology for assessing QoL. The Expanded 
Prostate Cancer Index Composite (EPIC) is a globally used tool to measure QoL after 
PCa treatment that comprises urinary, bowel, sexual, and hormonal domains. 
Acknowledging the need for such a tool applicable to Korean PCa patients, we trans-
lated EPIC into Korean and validated the new version.
Materials and Methods: The Korean version of EPIC was devised by translation, 
back-translation, and reconciliation. Subsequently, we randomly selected 153 patients 
with localized PCa treated with radical perineal prostatectomy (67, 43.8%), radical ret-
ropubic prostatectomy (19, 12.4%), laparoscopic radical prostatectomy (12, 7.8%), ro-
bot-assisted laparoscopic radical prostatectomy (36, 23.5%), and high-intensity focused 
ultrasound ablation of the prostate (19, 12.4%) and asked them to complete EPIC. 
Reliability was assessed by test-retest correlation and Cronbach’s alpha. Validity was 
assessed by factor analysis, interscale correlation, and correlation with Functional 
Assessment of Cancer Therapy-Prostate (FACT-P).
Results: Test-retest correlation and Cronbach’s alpha were high in each of the domains 
(0.92, 0.91, 0.76, 0.84 and 0.86, 0.84, 0.92, 0.83, p＜0.0001). Interscale correlation 
among the domains was low (r＜0.37), which indicated that EPIC is composed of proper 
domains. Interscale correlation between the function and bother subscales was high 
(0.94, 0.81, 0.84 and 0.80, p＜0.0001). EPIC domains had low correlation with FACT-P, 
permitting complementary use.
Conclusions: The Korean version of EPIC was developed by a proper process, as evident 
by its high reliability and validity. Therefore, it is a reliable, comprehensive, systematic 
method that evaluates QoL in Korean patients after PCa treatment. Furthermore, it 
can be adapted as an objective methodology for research globally.
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Prostate cancer (PCa) is the fifth most common cancer in 
the Korean male population as well as the most rapidly 
growing cancer in the population group [1]. Owing to early 
diagnosis through the introduction of prostate-specific anti-
gen (PSA), followed by transrectal ultrasonography-guided 
prostate biopsy and the development of multiple advanced 
treatment modalities, early-diagnosed, localized PCa ach-
ieves a survival rate of close to 100% [2]. However, as life 
expectancy increases and the average age at the time of 
cancer diagnosis decreases, quality of life (QoL) after PCa 
treatment becomes increasingly important. Today’s medi-
cal knowledge and technology offer a variety of choices of Korean J Urol 2010;51:601-612
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PCa treatment modalities, such as radical perineal prosta-
tectomy (RPP), radical retropubic prostatectomy (RRP), 
laparoscopic radical prostatectomy (LRP), robot-assisted 
laparoscopic radical prostatectomy (RLRP), high-intensity 
focused ultrasound ablation of the prostate (HIFU), cryo-
therapy, external beam radiotherapy (EBRT), brachy-
therapy, and proton beam therapy. However, recent data 
show no definite evidence favoring one modality over an-
other [3]. When patients are faced with the choice, it is very 
hard to choose a particular treatment. Hence, the responsi-
bility for suggesting the most appropriate treatment option 
for an individual patient rests with the urologist [4]. This 
is why QoL after PCa treatment is becoming an important 
issue. 
Although multiple methodologies have been used to 
evaluate the QoL of cancer patients, definitive and univer-
sally accepted methodologies that focus on PCa have been 
rare until now. As such, questionnaires for chronic illnesses 
or general cancer were adapted or individual symptoms 
and related QoL were studied. The Expanded Prostate Can-
cer Index Composite (EPIC) was developed by researchers 
at the University of Michigan and UCLA. EPIC expanded 
the UCLA-PCI (UCLA prostate cancer index) to evaluate 
health-related QoL in order to reflect PCa treatment-related 
symptoms and their negative impact more sensitively [5,6]. 
EPIC’s major categories include the urinary, bowel, and 
sexual symptoms that patients face following treatment of 
localized PCa [7]. Furthermore, a section to evaluate hor-
monal symptoms frequently associated with hormonal de-
privation and their consequence in QoL was added [6]. EPIC 
enables clinicians to evaluate the physical and mental as-
pects of QoL simultaneously. Since its advent, EPIC has 
been acknowledged a useful, systemic, and comprehensive 
tool that is widely used. However, there has not been any 
attempt to develop a Korean version of EPIC.
When translating a self-administered questionnaire in-
to a different language, special attention must be paid to 
accommodate linguistic as well as cultural differences, and 
the questionnaire must also be verified through a proper 
validation procedure [8]. The Korean version of EPIC was 
developed by the aforementioned criteria to faithfully re-
flect the virtues of the original version. 
MATERIALS AND METHODS
1. Composition of EPIC
EPIC consists of 50 questions in total divided into four do-
mains: bowel, urinary, sexual, and hormonal aspects. Each 
domain is divided into two categories, functional and both-
er subscales, which evaluate types of symptoms and the ex-
tent of suffering. In addition, the urinary domain is sub-
divided into incontinence and irritative/obstructive sub-
scales, according to the symptom characteristics. Each 
question is in the Likert scale format with scores from 0 to 
100. The higher the score, the higher the QoL [6]. 
2. Development of the Korean version of EPIC (Appendix)
We initiated this process by obtaining the initial authors’ 
agreements. EPIC was translated into Korean by two profi-
cient translators; this was the forward translation. The 
prototype of the Korean version of EPIC was generated by 
combining these two manuscripts with the inputs of the au-
thors, one other urologist, and two translators. Subsequen-
tly, this prototype was translated into English by another 
proficient translator; this was the back translation. The fi-
nal version of the Korean EPIC was developed after a sec-
ond round of compromise and discussions. 
A pilot test was performed on 10 PCa patients treated 
with radical prostatectomy at the Samsung Medical Center 
to determine the extent of comprehension and difficulties. 
We then finalized the Korean version of EPIC.
3. Patient inclusion and validation 
From March 2009 to May 2009, a total of 153 patients treated 
and followed up for localized PCa were randomized during 
their regular visit at the Samsung Medical Center. The 
mean interval from PCa treatment to the study was 27 
months. The research protocol was approved by the 
Institutional Review Board and all interviews were per-
formed after obtaining informed consent from patients. 
Treatment modalities included RPP (67 patients, 43.8%), 
RRP (19 patients, 12.4%), LRP (12 patients, 7.8%), RLRP 
(36 patients, 23.5%), and HIFU (19 patients, 12.4%). Of all 
patients, 37 patients (24.0%) underwent hormonal treat-
ment (adjuvant treatment: 11 patients; neo-adjuvant treat-
ment plus adjuvant treatment: 22 patients; orchiectomy: 
2 patients; neo- adjuvant treatment: 2 patients). All pa-
tients were requested to answer the Korean version of 
EPIC and the Functional Assessment of Cancer Therapy- 
Prostate (FACT-P) - a previously proven questionnaire - si-
multaneously for comparison. To confirm test-retest reli-
ability, a repeat EPIC questionnaire was mailed out 4 
weeks later without informing patients of the intent to con-
duct the same questionnaire. In total, 78 patients replied 
to the retest mail.
4. Statistical analysis 
Statistical analyses of reliability and validity were per-
formed with SPSS for Windows (version 17.0 K, SPSS, 
Chicago, IL, USA). To confirm reliability, test-retest corre-
lation was assessed by intra-class correlation coefficient, 
and the internal consistency of each subscale was assessed 
by Cronbach’s alpha coefficient. To confirm validity, the 
propriety of composition of the domain categories, inter- 
scale correlation between the function and bother sub-
scales of each domain, and the inter-scale correlation 
among each subscale were analyzed. The propriety of com-
position of the domain categories was verified by factor 
analysis with varimax rotation. Inter-scale correlation be-
tween the function and bother subscales of each domain 
and the inter-scale correlation among each of the subscales 
for independency and redundancy were verified by Spear-
man’s correlation coefficient.Korean J Urol 2010;51:601-612
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TABLE 1. Treatment modality and clinicopathological charac-
teristics of the patients
Parameters
Mean age±SD (years) 68.2±6.18 
   Primary treatment
      RPP (%)   67 (43.8)
      RRP (%)   19 (12.4)
      LRP (%) 12 (7.8)
      RLRP (%)   36 (23.5)
      HIFU (%)   19 (12.4)
   Hormonal therapy
a    37 (24.0)
Mean pretreatment PSA±SD (ng/ml) 11.7±10.7
   Gleason score
      ≤6 (%)   66 (43.1)
      7 (%)   56 (36.6)
      ≥8 (%)   31 (20.2)
   Clinical T-stage
b
      T1 (%)   30 (19.6)
      T2 (%)   88 (57.5)
      T3 (%)   35 (22.9)
RPP: radical perineal prostatectomy, RRP: radical retropubic 
prostatectomy, LRP: laparoscopic radical prostatectomy, RLRP: 
robot-assisted laparoscopic radical prostatectomy, HIFU: high- 
intensity focused ultrasound ablation of prostate, PSA: prostate-
specific antigen, 
a: neo-adjuvant treatment: 2 patients, adjuvant
treatment: 11 patients, neo-adjuvant treatment＋adjuvant treat-
ment: 22 patients, orchiectomy: 2 patients, 
b: 2002 TNM staging 
system.
TABLE 2. Reliability assessment of the Korean version EPIC by 
test-retest correlation and Cronbach’s alpha 
EPIC Item  Test-retest  Cronbach’s
domain number reliability  alpha
Domain 50
   Urinary 12 0.918 0.861
   Bowel 14 0.909 0.844
   Sexual 13 0.761 0.923
   Hormonal 11 0.835 0.827
Subscale
Urinary
   Function 5 0.931 0.575
   Bother 7 0.877 0.786
   Incontinence 4 0.896 0.756
   Irritation/obstruction 7 0.936 0.770
Bowel
   Function 7 0.942 0.602
   Bother 7 0.840 0.763
Sexual
   Function 9 0.739 0.889
   Bother 4 0.722 0.748
Hormonal
   Function 5 0.856 0.568
   Bother 6 0.630 0.716
Test-retest reliability greater than 0.70 means that the reliability 
is high. A Cronbach’s alpha coefficient for the individual subscale
greater than 0.70 means that the internal consistency is high. 
EPIC: Expanded Prostate Cancer Index Composite. p＜0.0001 
TABLE 3. Validity assessment of the Korean version of EPIC by Spearman’s correlation coefficients between the function and bother
subscales
Urinary Bowel Sexual Hormonal
Function Bother Function Bother Function Bother Function Bother
Urinary
   Function 1.00 -    -    -  -  -  - -
   Bother 0.940
a 1.00    -    -  -  -  - -
Bowel
   Function 0.223   0.295   1.00    -  -  -  - -
   Bother 0.279   0.319       0.806
a   1.00  -  -  - -
Sexual
   Function 0.260   0.223 −0.027 −0.004 1.00  -  - -
   Bother 0.276   0.282   0.30 −0.023    0.838
a 1.00  - -
Hormonal
   Function 0.335   0.353     0.270     0.326   0.038   0.072 1.00 -
   Bother 0.234   0.262     0.340     0.367   0.000   0.086     0.804
a 1.00
A value of Spearman’s correlation greater than 0.40 between subscales indicates that the scales are meaningfully related, and a value
greater than 0.70 between subscales indicates that they are highly related. EPIC: Expanded Prostate Cancer Index Composite, 
a: Spearman’s
correlation coefficients between function and bother subscale ≥0.7 indicates that the bother subscales of each domain were highly corre-
lated with the function subscales. p＜0.0001
RESULTS
The mean age of the patients was 68±6.18 years. All pa-
tients were treated and followed up for localized PCa at the 
Samsung Medical Center. The patients’ treatment modal-
ity and clinicopathological characteristics are summarized 
in Table 1. The study sample included diverse treatments 
groups, Gleason scores, and T stages of PCa.
The reliability of each domain and subscale is summar-
ized in Table 2. Test-retest correlations of the urinary, bow-
el, sexual, and hormonal domains were 0.92, 0.91, 0.76, and 
0.84, respectively, and all exhibited very strong correla-Korean J Urol 2010;51:601-612
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TABLE 4. Validity assessment of the Korean version of EPIC by 
Spearman’s correlation coefficients between EPIC domains and 
FACT-P
Urinary Bowel Sexual Hormonal 
    Scales                                    FACT-P
sum sum sum sum
Urinary sum 1 - - - -
Bowel sum 0.400 1 - - -
Sexual sum 0.264 0.074 1 - -
Hormonal sum 0.347 0.376 0.055 1 -
FACT-P 0.238 0.117 0.031 0.149 1
A value of Spearman’s correlation greater than 0.40 between sub-
scales indicates that the scales are meaningfully related, and a 
value greater than 0.70 between subscales indicates that they are
highly related. EPIC: Expanded Prostate Cancer Index Compo-
site, FACT-P: Functional Assessment of Cancer Therapy-Prostate.
p＜0.0001
tions (p＜0.0001). Cronbach’s alpha coefficients of each do-
main were 0.86, 0.84, 0.92, and 0.83, respectively (p＜ 
0.0001). The internal consistency of all domains, according 
to Cronbach’s alpha coefficients, was very high. Therefore, 
the reliability of the Korean version of EPIC was validated. 
In the factor analysis, all answers were evaluated with 
varimax rotation. While all translated questions on the uri-
nary, bowel, and sexual domains coincided with the origi-
nal version of EPIC, the hormonal domain questions were 
divided into three subcategories. However, we concluded 
that it appeared acceptable, considering that the hormonal 
domain contained diverse symptom spans, such as hot 
flushes, breast tenderness, depression, lack of energy, and 
weight loss. The interscale correlations between each do-
main were low (r＜0.37). From these results, we concluded 
that all domains were divided properly and the in-
dependency of each domain was confirmed. To confirm that 
the subscale of each domain adequately reflected the 
health-related QoL of PCa patients, the inter-scale correla-
tions of each of the function and bother subscales were eval-
uated (Table 3). The Spearman correlation coefficients (r) 
of each domain were 0.94, 0.81, 0.84, and 0.80 (p＜0.0001), 
which means that each subscale had a strong correlation. 
We interpreted this to mean that the bother subscales of 
each domain were highly correlated with the function 
subscales.
The correlation between each domain score of the Korean 
version of EPIC and a previously validated and currently 
used questionnaire, FACT-P, was analyzed. FACT-P and 
each domain of EPIC showed low correlation (r＜0.24), 
which could be interpreted to mean that these two questio-
nnaires could be used complementarily without redun-
dancy in the evaluation of QoL in PCa patients (Table 4).
DISCUSSION
PCa is the second most commonly diagnosed cancer and the 
sixth most common cause of death in males worldwide [9]. 
Its prevalence is also confirmed by recent data (2004-2006) 
that 1 in every 6 males experience PCa in their lifetime [10]. 
In fact, PCa has shown the fastest growth in incidence, 
which it may explain the explosively increasing interest in 
this disease in the general population in Korea [1]. Without 
doubt, the primary goal of PCa treatment is to improve 
survival. Despite the development of diverse modalities to 
manage PCa, only scarce comparative studies on the 
long-term survival rates of these modalities are available, 
limiting the data available for patients regarding com-
parative survival associated with different treatment 
modalities.   
Moreover, QoL after the treatment of PCa is important 
because of three characteristics of the disease: most PCa 
progresses slowly, most treatments leave certain residual 
symptoms, and the average survival after treatment is 
gradually increasing [11,12]. Hence, QoL research could 
provide additional information for choosing a treatment. 
Furthermore, the report that about 16% of patients who un-
dergo treatment for localized PCa regret their treatment 
choice emphasizes the importance of providing the most 
comprehensive information possible to patients about the 
treatments before they choose their treatment [13,14]. 
The most common complications after treatment of lo-
calized PCa are urinary incontinence, bleeding, bowel tox-
icity, and erectile dysfunction [7]. More specifically, 4-50% 
of patients suffer mild stress incontinence, 0-15% suffer se-
vere stress incontinence, 0.5-15% suffer bladder neck stric-
ture [14], and 60-90% suffer erectile dysfunction after sur-
gical management [7]. In the case of EBRT, it has been re-
ported that more than 12% of patients experience a moder-
ate to severe degree of urinary incontinence, 20-50% expe-
rience diarrhea, more than 39% experience rectal pain, and 
80% experience erectile dysfunction [14]. Reports on QoL 
after HIFU are inadequate, but it has been reported that 
approximately 12% of patients experience stress urinary 
incontinence and 55-70% experience erectile dysfunction 
[14]. Hormonal therapy for PCa also severely affects QoL. 
Prevalences of 50-100% for erectile dysfunction, 13-70% for 
gynecomastia, and 55-80% for hot flushes in treated pa-
tients have been reported [15]. This is why close attention 
needs to be paid to complications when we consider QoL af-
ter PCa treatment.
Although there are multiple methodologies to evaluate 
QoL in chronically ill or cancer patients, such as FACIT, 
SF-36, and FACT-G, a more specialized method for exam-
ining the QoL of PCa patients treated with multiple modal-
ities has not been established. As such, these method-
ologies have been used as research tools to study QoL after 
PCa treatments, despite their limitations, which include 
a lack of reflection in symptom severity, bother, limitation 
of one’s life, and eventually quality of life. 
FACT-P, a recently developed questionnaire to over-
come this limitation, has been translated into Korean and 
has been validated [16]. It was achieved by extending 
FACT-G, adding certain prostate-related symptoms, 
which allows it to provide objective and consistent data on 
cancer treatment and rough prostate-related symptoms. Korean J Urol 2010;51:601-612
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However, its limitation lies in that the research does not 
offer detailed information on symptom-related QoL after 
PCa treatment. In contrast, EPIC is systemically organized 
with common symptom-related domains and is divided in-
to the physical and mental aspects of QoL [17]. In addition, 
hormone-related symptom domains were added, which 
were neglected in other studies on QoL [6]. These proper-
ties were supported by our results that showed a low corre-
lation coefficient between EPIC and FACT-P (r＜−0.1). 
This result can be interpreted to mean that EPIC and 
FACT-P can be used simultaneously with complementary 
purposes, or indeed independently. 
To describe the word ‘domain’, one translator proposed 
‘계’ initially. However, we revised this to ‘영역’ because ‘계’ 
appeared to be awkward. There was a minor opinion en-
quiring about ‘leaked urine’ in Question 1 and ‘urinary con-
trol’ in Question 4 in the urinary domain, which appeared 
to have similar meaning in Korean, but we agreed that 
these expressions were acceptable, considering the context 
of the initial questionnaire. In the bowel domain, ‘rectal 
pain’ was a problem because it was ambiguous and difficult 
to distinguish from rectum; therefore, we changed ‘rectal 
pain’ to ‘항문  통증’, meaning anal pain. In the hormonal do-
main, we translated ‘hot flush’ to ‘열감’ initially; however, 
it was then changed to ‘일과성  열감’ because ‘열감’ was con-
fused with fever sensation. All translators chose ‘유방의  민
감도’ for ‘Breast tenderness’, but we substituted this ex-
pression with ‘유방통증’. There were two opinions on 
‘small’, ‘moderate’, and ‘big’ on the bother subscale of each 
domain. One was ‘조금’, ‘보통’ and ‘큰’; the other was ‘경증’, 
‘중등도’ and ‘중증’. One raised an objection to the first opin-
ion because the word ‘보통’ is usually used in case of normal 
and it was confusing. But the majority of our group came 
to consensus on the first opinion, because ‘중증의  문제가  됨’ 
was somewhat awkward and ‘보통’ was not confusing in 
this context.  
Although studies on PCa QoL with EPIC are on the in-
crease, there are not enough efforts to publish the result 
of its translation into other languages and subsequent 
validation. As far as we know, Japanese [18], Spanish [19], 
and partially Dutch [20] versions of EPIC have been 
published. It is probably because EPIC is not yet general-
ized to urologists or other oncologists. However, according 
to our experience, large numbers of questions and ad-
vanced patient age may explain this. EPIC consists of 50 
questions that could be excessive for elderly patients who 
have difficulties maintaining concentration and compli-
ance. In our cases, many patients complained that it took 
a lot of time to complete the informed consent, EPIC, and 
FACT-P simultaneously, mainly due to poor vision. After 
realizing this, we decided to compare EPIC with FACT-P 
only after consulting with a statistician, and arranged for 
a monitor until completion of the questionnaire. This could 
have improved patient compliance. With these processes, 
we achieved reliability and validity that can be compared 
with the original version of EPIC. An outstanding point of 
this research is the diverse inclusion of target patients. In 
other words, we included patients who underwent RPP, 
RRP, LRP, RLRP, and HIFU. Therefore, our validation of 
the Korean version of EPIC in this group of patients can 
offer a more solid basis to the outcomes on QoL after PCa 
treatment.
CONCLUSIONS
The Korean version of EPIC was developed to reflect the 
original version of EPIC and was adapted to the Korean cul-
ture and language. Reliability and validity were accept-
able; therefore, it can be used as a validated tool to evaluate 
treatment-related QoL in Korean PCa patients. Further-
more, it can be used as an objective reference to compare 
the mental and physical aspects of various treatment 
modalities. The Korean version of EPIC can be accepted as 
an accurate methodology with cross-cultural variety  in in-
ternational multicenter research. 
From the patient’s perspective, the Korean version of 
EPIC can offer important clues on choosing a treatment op-
tion by providing knowledge about differences in QoL asso-
ciated with individual modalities. In addition, it may help 
patients to deal with the postoperative state and overcome 
complications with appropriate and early interventions.
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  Appendix
＜ The Expanded Prostate Cancer Index Composite >
본  설문은  전립선암  환자의  삶의  질을  측정하기  위해  만들어졌습니다. 정확한  평가를  위해서는  모든  질문에  솔직하게  답변해주
시는  것이  무엇보다  중요합니다.
본  설문의  기밀은  철저히  지켜질  것입니다.
날  짜  :  __________ 년    ______ 월    ______ 일
성  명  :  ______________________
배뇨  영역
다음  문항은  배뇨기능에  대한  내용입니다. 최근  4주간의  상태를  고려하여  답해  주십시오.
1. 지난  4주  동안 얼마나  자주  소변이  새어  나왔습니까?              
 
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
2. 지난  4주  동안 얼마나  자주  소변에  피가  섞여  나왔습니까?          
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
3. 지난  4주  동안 소변  볼  때  얼마나  자주  통증이나  따가움을  느꼈습니까?       
         
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
4. 다음  중  지난  4주  동안 귀하의  소변조절  상태를  가장  잘  설명하는  것은  어느  것입니까?
소변  조절이  전혀  안  된다 →    1 
자주  소변이  뚝뚝  떨어진다 →    2
가끔  소변이  뚝뚝  떨어진다 →    3 
소변조절을  완벽하게  한다  →    4Korean J Urol 2010;51:601-612
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5. 지난  4주  동안 귀하는  소변이  새는  증상으로  인해  하루에  몇  장의  패드  또는  성인용  기저귀를  사용했습니까?
사용하지  않았다 →    0
하루에  한  장  →    1
하루에  두  장  →    2 
하루에  세  장  이상 →    3
6. 아래의  예를  참고하여  각  사항  중  귀하에게  해당되는  것이  있으면  그  정도가  얼마나  심한지  해당되는  번호에  표시하시오. 
예)  아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
a. 소변이  새거나  뚝뚝  떨어짐 0   1   2   3   4
b. 소변  중  통증이나  따가움을  느낌 0   1   2   3   4
c. 배뇨  중  피가  섞여  나옴 0   1   2   3   4
d. 소변  줄기가  약하거나  다  나오지  않음 0   1   2   3   4
e. 소변을  보기  위해  자다가  일어남 0   1   2   3   4
f. 낮  동안에  소변을  자주  봄 0   1   2   3   4
7. 전반적으로  볼  때  지난  4주  동안 귀하의  소변  기능의  문제는  어느  정도입니까?
아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
배변  영역
다음  문항은  배변기능에  대한  내용입니다. 최근  4주간의  상태를  고려하여  답해  주십시오.
8. 지난  4주  동안 얼마나  자주  대변절박  (대변이  곧  나올  것  같이  느껴졌으나  실제로는  대변이  나오지  않은  경우)이  있습니까?  
      
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
9. 대변이  조절되지  않아  새어  나온  적이  얼마나  자주  있습니까?      
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5Korean J Urol 2010;51:601-612
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10. 귀하는  얼마나  자주  무른  변이나  설사  (형체가  없거나  대부분  물이거나  혹은  걸쭉한)를  경험했습니까?                       
전 혀  없 다       →    1
어쩌다  한  번씩      →    2
절반  정도  그렇다    →    3
대부분  그렇다      →    4
항상  혹은  거의  그렇다    →    5
11. 지난  4주  동안 얼마나  자주  피  섞인  대변이  나왔습니까?       
   
전 혀  없 다       →    1
어쩌다  한  번씩      →    2
절반  정도  그렇다    →    3
대부분  그렇다      →    4
항상  혹은  거의  그렇다    →    5
12. 지난  4주  동안 배변  시  얼마나  자주  통증을  느꼈습니까?          
전 혀  없 다       →    1
어쩌다  한  번씩      →    2
절반  정도  그렇다    →    3
대부분  그렇다      →    4
항상  혹은  거의  그렇다    →    5
13. 지난  4주  동안 일반적으로  하루에  몇  번  배변했습니까?
두  번  이하    →    1
서 너  번       →    2
다섯  번  이상    →    3
14. 지난  4주  동안 얼마나  자주  복부, 골반, 항문  등에서  심한  통증을  느꼈습니까? 
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
15. 아래의  예를  참고하여  각  사항  중  귀하에게  해당되는  것에  표시하시오.
 
예)  아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
a. 대변을  급하게  보고  싶음 0   1   2   3   4
b. 배변의  횟수가  늘어났음 0   1   2   3   4
c. 설사의  정도 0   1   2   3   4
d. 배변이  조절되지  않음 0   1   2   3   4
e. 대변에  피가  섞여  나옴       0   1   2   3   4
f. 복부, 골반, 항문의  통증         0   1   2   3   4Korean J Urol 2010;51:601-612
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16. 전반적으로  볼  때  지난  4주  동안 귀하의  배변  습관의  문제는  어느  정도입니까?
아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
 
성기능  영역
다음  문항은  성기능에  대한  내용입니다. 대부분의  질문들이  매우  개인적인  질문이지만  이  질문들이  귀하가  매일  직면하는 
문제들에  대해  우리가  이해하는  데  큰  도움을  줄  것입니다. 또한  이  정보들은  철저히  기밀이  유지될  것입니다. 최근  4주간의 
상태를  고려하여  답해  주십시오.
17. 아래  상자의  예를  참고하여  지난  4주  동안 각  사항  중  귀하에게  해당되는  번호에  표시하시오
예)  아주  미미하거나  없음    →    1
약 함       →    2    
보 통     →    3 
좋 음      →    4     
아주  좋음 →    5
a. 귀하의  성욕의  정도  1   2   3   4   5
b. 발기할  수  있는  능력 1   2   3   4   5
c. 오르가슴  (성적  절정)에  도달할  수  있는  능력 1   2   3   4   5
18. 지난  4주  동안 귀하는  본인의  평소  발기  상태를  질적으로  어떻게  평가하십니까?
전혀  없다 →    1
성행위를  할  만큼  단단하지  않다 →    2
자위행위와  전희만  할  수  있을  정도로  단단하다 →    3
성교를  할  만큼  단단하다 →    4
19. 지난  4주  동안 귀하는  본인의  발기가  얼마나  자주 된다고  평가하십니까?
내가  원했을  때  발기한  경우가  전혀  없다 →    1
내가  원했을  때  발기한  경우가  절반  이하이다 →    2
내가  원했을  때  발기한  경우가  절반  정도이다 →    3
내가  원했을  때  발기한  경우가  절반  이상이다 →    4
내가  원했을  때  언제나  발기하였다 →    5
20. 지난  4주  동안 아침이나  밤에  귀하가  잠에서  깨어나  보니  발기가  되어  있었던  경우가  얼마나  있었습니까?                   
전혀  없음      →    1
일주일에  한  번  이하    →    2
일주일에  한  번  정도    →    3 
일주일에  여러  차례    →    4
거의  매일      →    5Korean J Urol 2010;51:601-612
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21. 지난  4주  동안 어떠한  형태이든 성적인  행위를  하셨다면  얼마나  자주  했습니까?      
전혀  없음      →    1
일주일에  한  번  이하    →    2
일주일에  한  번  정도    →    3 
일주일에  여러  차례    →    4
거의  매일      →    5
22. 지난  4주  동안 귀하는  얼마나  자주  성교를  하였습니까?       
     
전혀  없음      →    1
일주일에  한  번  이하    →    2
일주일에  한  번  정도    →    3 
일주일에  여러  차례    →    4
거의  매일      →    5
23. 전반적으로  볼  때  지난  4주  동안 귀하의  성기능을  어떻게  평가하시겠습니까?
매우  약하다      →    1
약하다      →    2
보통이다    →    3
좋 다      →    4
아주  좋다  →    5
24. 아래의  예를  참고하여  각  사항  중  귀하에게  해당되는  번호에  표시하시오. 
예)  아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
a. 성욕의  정도 0   1   2   3   4
b. 발기할  수  있는  능력 0   1   2   3   4
c. 오르가슴  (성적  절정)에  이를  수  있는  능력 0   1   2   3   4
25. 전반적으로  볼  때  지난  4주  동안 귀하의  성적  기능에  관한  문제는  어느  정도입니까? 
아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
호르몬계
다음  문항은  호르몬기능에  대한  내용입니다. 최근  4주간의  상태를  고려하여  답해  주십시오.
26. 지난  4주  동안 얼마나  자주  열감을  겪었습니까?      
             
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5Korean J Urol 2010;51:601-612
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27. 지난  4주  동안 얼마나  자주  유방통을  겪었습니까?     
            
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
28. 지난  4주  동안 얼마나  자주  우울함을  느꼈습니까?         
        
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
29. 지난  4주  동안 얼마나  자주  기운이  없다고  느꼈습니까?        
    
하루에  한  번  이상 →    1
하루에  한  번  정도 →    2 
일주일에  한  번  이상 →    3
일주일에  한  번  정도 →    4
전혀, 또는  거의  없음 →    5
30. 지난  4주  동안 몸무게의  변화가  있었다면  얼마나  변하였습니까?
4.5 kg 이상  증가  →    1
4.5 kg 이하  증가  →    2
변화  없음    →    3 
4.5 kg 이하  감소  →    4
4.5 kg 이상  감소  →    5
31. 아래의  예를  참고하여  각  사항  중  귀하에게  해당되는  번호에  표시하시오. 
예)  아무  문제없음 →    0
아주  조금  문제가  됨 →    1
조금  문제가  됨  →    2
보통  정도  문제가  됨    →    3
큰  문제가  됨     →    4
a. 열감 0   1   2   3   4
b. 유방통/크기  증가 0   1   2   3   4
c. 체모가  빠짐 0   1   2   3   4
d. 우울함을  느낌 0   1   2   3   4
e. 기운이  없음 0   1   2   3   4
f. 몸무게의  변화 0   1   2   3   4
전반적인  만족도
32. 전반적으로  전립선암과  관련되어  귀하가  받은  치료법에  대해  어느  정도  만족하십니까?
매우  불만족      →    1
불만족    →    2
그저  그렇다    →    3
만 족     →    4
매우  만족    →    5